 Agile Therapeutics recently reported their Q2 earnings with a beat on EPS and a miss on revenue. The companys flagship product, Twirla, is already starting to display impressive growth trends. The market had a difficult time determining which direction it wants to take the share price, which has provided me an opportunity to add to my AGRX position. 